But every single ADR report can contribute to: Better patient safety Stronger drug safety databases Early signal detection Safer prescribing practices Improved public health decisions
Our results confirmed these findings
In a phase 3, double-blind, randomized, controlled trial, 2,539 adults with a body-mass index (BMI) of 30 or greater, or 27 or greater with at least one weight-related complication, were given weekly subcutaneous injections of tirzepatide (5 mg, 10 mg, or 15 mg) or a placebo for 72 weeks
They work through overlapping mechanisms and combining them would significantly increase side effect risks without proven additional benefits
However, their effectiveness can vary depending on individual patient factors such as baseline HbA1c, weight, other health conditions, and treatment adherence
This is perfectly fine